Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits

Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies. A retrospective analysis was performed of women who received platinum/bevacizumab (PB) chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamorano, Abigail S., Wan, Leping, Powell, Matthew A., Massad, L. Stewart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720391/
https://www.ncbi.nlm.nih.gov/pubmed/29234709
http://dx.doi.org/10.1016/j.gore.2017.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720391/
https://www.ncbi.nlm.nih.gov/pubmed/29234709
http://dx.doi.org/10.1016/j.gore.2017.09.003

Ejemplares similares